Published in Hypertens Res on November 01, 2002
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail (2012) 1.62
Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem. J Geriatr Cardiol (2015) 0.95
Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. J Appl Physiol (1985) (2015) 0.83
Cardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone. J Am Heart Assoc (2014) 0.81
The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy. Hypertens Res (2015) 0.81
Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review. J Am Heart Assoc (2015) 0.80
Aldosterone and the heart: still an unresolved issue? Front Endocrinol (Lausanne) (2014) 0.79
Aldosterone and aldosterone antagonists in cardiac disease: what is known, what is new. Am J Cardiovasc Dis (2011) 0.78
Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure. Methodist Debakey Cardiovasc J (2016) 0.75
Left Ventricular Diastolic Function in Nigerian Patients with Essential Hypertension: A Retrospective Study to Compare Angiotensin Converting Enzyme Inhibitors, Calcium Channel Blockade or Their Combination. Arch Drug Inf (2008) 0.75
SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet (2008) 8.63
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet (2008) 2.89
Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension (2006) 2.89
Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension (2010) 2.37
Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) (2002) 2.26
Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest (2004) 2.24
Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine. Hypertens Res (2010) 2.18
Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens (2011) 1.75
Importance of rostral ventrolateral medulla neurons in determining efferent sympathetic nerve activity and blood pressure. Hypertens Res (2011) 1.72
Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab (2004) 1.69
Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol (2006) 1.67
Dimethylarginine dimethylaminohydrolase 2 increases vascular endothelial growth factor expression through Sp1 transcription factor in endothelial cells. Arterioscler Thromb Vasc Biol (2006) 1.62
Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension (2003) 1.59
Development of enzyme-linked immunosorbent assays for urinary thiazide-sensitive Na-Cl cotransporter measurement. Am J Physiol Renal Physiol (2013) 1.59
Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial. J Hypertens (2014) 1.56
PPAR(gamma)2 gene Pro12Ala polymorphism may influence serum level of an adipocyte-derived protein, adiponectin, in the Japanese population. Metabolism (2002) 1.56
Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension (2008) 1.54
Role of endothelium-derived hyperpolarizing factor in ACE inhibitor-induced renal vasodilation in vivo. Hypertension (2004) 1.49
Expression of the Na+/H+ exchanger regulatory protein family in genetically hypertensive rats. J Hypertens (2004) 1.49
Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. Hypertens Res (2010) 1.47
Monosynaptic excitatory connection from the rostral ventrolateral medulla to sympathetic preganglionic neurons revealed by simultaneous recordings. Hypertens Res (2008) 1.47
T-cell-mediated autoimmunity may be involved in fulminant type 1 diabetes. Diabetes Care (2002) 1.45
Developmental activity of the renin-angiotensin system during the "critical period" modulates later L-NAME-induced hypertension and renal injury. Hypertens Res (2007) 1.45
Cloning and characterization of a novel gene promoting ureteric bud branching in the metanephros. Kidney Int (2003) 1.45
High-density association study and nomination of susceptibility genes for hypertension in the Japanese National Project. Hum Mol Genet (2007) 1.44
Association of blood pressure control and metabolic syndrome with cardiovascular risk in elderly Japanese: JATOS study. Am J Hypertens (2011) 1.44
Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial. Circ J (2009) 1.40
Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan. Hypertens Res (2006) 1.39
Ca2+ channel subtypes and pharmacology in the kidney. Circ Res (2007) 1.38
Correlation between serum resistin level and adiposity in obese individuals. Obes Res (2003) 1.36
Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ Res (2004) 1.33
Heart failure causes cholinergic transdifferentiation of cardiac sympathetic nerves via gp130-signaling cytokines in rodents. J Clin Invest (2010) 1.33
Musculin/MyoR is expressed in kidney side population cells and can regulate their function. J Cell Biol (2005) 1.31
Snail1 is involved in the renal epithelial-mesenchymal transition. Biochem Biophys Res Commun (2007) 1.29
Rho-kinase as a molecular target for insulin resistance and hypertension. FASEB J (2005) 1.22
Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int (2003) 1.21
Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism (2002) 1.18
CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis. J Immunol (2004) 1.16
Extracellular matrix glycoprotein biglycan enhances vascular smooth muscle cell proliferation and migration. Circ Res (2004) 1.13
Intrarenal injection of bone marrow-derived angiogenic cells reduces endothelial injury and mesangial cell activation in experimental glomerulonephritis. J Am Soc Nephrol (2005) 1.11
Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens (2005) 1.07
Smooth and cardiac muscle-selective knock-out of Kruppel-like factor 4 causes postnatal death and growth retardation. J Biol Chem (2010) 1.06
The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Hypertens Res (2008) 1.03
Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. Am J Kidney Dis (2005) 1.03
Ubc9 and Protein Inhibitor of Activated STAT 1 Activate Chicken Ovalbumin Upstream Promoter-Transcription Factor I-mediated Human CYP11B2 Gene Transcription. J Biol Chem (2004) 1.03
Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res (2005) 1.02
Systemic administration of IL-18 promotes diabetes development in young nonobese diabetic mice. J Immunol (2003) 1.02
Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res (2004) 1.02
ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Rev Cardiovasc Ther (2008) 1.01
FHL2, UBC9, and PIAS1 are novel estrogen receptor alpha-interacting proteins. Endocr Res (2004) 1.00
Vessel- and vasoconstrictor-dependent role of rho/rho-kinase in renal microvascular tone. J Vasc Res (2003) 1.00
MPO-ANCA associated crescentic glomerulonephritis with numerous immune complexes: case report. BMC Nephrol (2012) 0.99
Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res (2004) 0.98
Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension. Clin Exp Hypertens (2006) 0.98
Gene transfer of truncated IkappaBalpha prevents tubulointerstitial injury. Kidney Int (2003) 0.98
The combination therapy of hypertension to prevent cardiovascular events (COPE) trial: rationale and design. Hypertens Res (2005) 0.98
Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. Hypertens Res (2012) 0.98
Transient receptor potential channels in rat renal microcirculation: actions of angiotensin II. Kidney Int (2002) 0.97
Fibroblast expression of an IκB dominant-negative transgene attenuates renal fibrosis. J Am Soc Nephrol (2010) 0.97
Kruppel-like factor 4 contributes to high phosphate-induced phenotypic switching of vascular smooth muscle cells into osteogenic cells. J Biol Chem (2012) 0.97
Electrophysiological properties of rostral ventrolateral medulla neurons in angiotensin II 1a receptor knockout mice. Hypertension (2005) 0.96
Role of Rho-kinase and p27 in angiotensin II-induced vascular injury. Hypertension (2005) 0.96
Relationships between serum soluble leptin receptor level and serum leptin and adiponectin levels, insulin resistance index, lipid profile, and leptin receptor gene polymorphisms in the Japanese population. Metabolism (2004) 0.96
Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients. Hypertens Res (2009) 0.95
Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9. J Biol Chem (2006) 0.95
Prepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive rats. Nephron (2002) 0.95
Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol (2007) 0.95
Altered renal microvascular response in Zucker obese rats. Metabolism (2002) 0.95
GPR40 gene Arg211His polymorphism may contribute to the variation of insulin secretory capacity in Japanese men. Metabolism (2005) 0.95
Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation. J Pharmacol Sci (2005) 0.95
Leukemia inhibitory factor is involved in tubular regeneration after experimental acute renal failure. J Am Soc Nephrol (2003) 0.94
Role of Krüppel-like factor 4 and its binding proteins in vascular disease. J Atheroscler Thromb (2014) 0.94
Smooth muscle-selective inhibition of nuclear factor-κB attenuates smooth muscle phenotypic switching and neointima formation following vascular injury. J Am Heart Assoc (2013) 0.94
Down-regulation of Mcl-1 by inhibition of the PI3-K/Akt pathway is required for cell shrinkage-dependent cell death. Biochem Biophys Res Commun (2002) 0.94
Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice. Am J Physiol Endocrinol Metab (2003) 0.93
Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant (2002) 0.93
Role of actions of calcium antagonists on efferent arterioles--with special references to glomerular hypertension. Am J Nephrol (2003) 0.92
High frequency of valpha24(+) vbeta11(+) T-cells observed in type 1 diabetes. Diabetes Care (2002) 0.92
Selective depletion of mouse kidney proximal straight tubule cells causes acute kidney injury. Transgenic Res (2011) 0.92
Rostral ventrolateral medulla neurons of neonatal Wistar-Kyoto and spontaneously hypertensive rats. Hypertension (2002) 0.91
Vitamin D receptor gene polymorphism affects onset pattern of type 1 diabetes. J Clin Endocrinol Metab (2003) 0.91
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens Res (2003) 0.91
Expression and regulation of nuclear receptor coactivators in glucocorticoid action. Mol Cell Endocrinol (2002) 0.91
NF-kappaB-dependent increase in intrarenal angiotensin II induced by proteinuria. Kidney Int (2005) 0.90
Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study. Hypertens Res (2006) 0.90